124 related articles for article (PubMed ID: 37718272)
1. Investigating the methods and characteristics of the trafficking of performance and image enhancing drugs in Australia.
Dunn M; Bright D; Fletcher P
Drug Alcohol Rev; 2024 Jan; 43(1):278-282. PubMed ID: 37718272
[TBL] [Abstract][Full Text] [Related]
2. Across the spectrum of legality: The market activities of influencers specialized in steroids and other performance and image enhancing drugs.
Paoli L; Joseph Cox LT
Int J Drug Policy; 2024 Jan; 123():104246. PubMed ID: 37979285
[TBL] [Abstract][Full Text] [Related]
3. Health care engagement behaviors of men who use performance- and image-enhancing drugs in Australia.
Jacka B; Larance B; Copeland J; Burns L; Farrell M; Jackson E; Degenhardt L
Subst Abus; 2020; 41(1):139-145. PubMed ID: 31545138
[No Abstract] [Full Text] [Related]
4. Information sought, information shared: exploring performance and image enhancing drug user-facilitated harm reduction information in online forums.
Tighe B; Dunn M; McKay FH; Piatkowski T
Harm Reduct J; 2017 Jul; 14(1):48. PubMed ID: 28732534
[TBL] [Abstract][Full Text] [Related]
5. Performance and image enhancing drug interventions aimed at increasing knowledge among healthcare professionals (HCP): reflections on the implementation of the Dopinglinkki e-module in Europe and Australia in the HCP workforce.
Atkinson AM; van de Ven K; Cunningham M; de Zeeuw T; Hibbert E; Forlini C; Barkoukis V; Sumnall HR
Int J Drug Policy; 2021 Sep; 95():103141. PubMed ID: 33549466
[TBL] [Abstract][Full Text] [Related]
6. Investigating the impact of COVID-19 on performance and image enhancing drug use.
Dunn M; Piatkowski T
Harm Reduct J; 2021 Dec; 18(1):124. PubMed ID: 34863199
[TBL] [Abstract][Full Text] [Related]
7. Social suppliers: Exploring the cultural contours of the performance and image enhancing drug (PIED) market among bodybuilders in the Netherlands and Belgium.
van de Ven K; Mulrooney KJ
Int J Drug Policy; 2017 Feb; 40():6-15. PubMed ID: 27574781
[TBL] [Abstract][Full Text] [Related]
8. Consumption in contrast: The politics of comparison in healthcare practitioners' accounts of men who inject performance and image-enhancing drugs.
Seear K; Moore D; Fraser S; Fomiatti R; Aitken C
Int J Drug Policy; 2020 Nov; 85():102883. PubMed ID: 32798925
[TBL] [Abstract][Full Text] [Related]
9. Health risk and health seeking behaviours among people who inject performance and image enhancing drugs who access needle syringe programs in Australia.
Van de Ven K; Maher L; Wand H; Memedovic S; Jackson E; Iversen J
Drug Alcohol Rev; 2018 Nov; 37(7):837-846. PubMed ID: 29968372
[TBL] [Abstract][Full Text] [Related]
10. Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs.
Larance B; Degenhardt L; Copeland J; Dillon P
Drug Alcohol Rev; 2008 Nov; 27(6):679-86. PubMed ID: 18825549
[TBL] [Abstract][Full Text] [Related]
11. Men, bodywork, health and the potentiality of performance and image-enhancing drugs.
Dowsett GW; Duncan D; Waling A; Angelides S; Nourse G
Health Sociol Rev; 2023 Nov; 32(3):341-356. PubMed ID: 36577038
[TBL] [Abstract][Full Text] [Related]
12. Is the use of performance and image enhancing drugs (PIEDs) in women an issue of concern? The findings from a stakeholder consultation.
Dunn M; Piatkowski TM; Robertson J; Lamon S
J Sci Med Sport; 2023 Nov; 26(11):574-579. PubMed ID: 37684155
[TBL] [Abstract][Full Text] [Related]
13. An overview on performance and image enhancing drugs (PIEDs) confiscated in Italy in the period 2017-2019.
Odoardi S; Mestria S; Biosa G; Valentini V; Federici S; Strano Rossi S
Clin Toxicol (Phila); 2021 Jan; 59(1):47-52. PubMed ID: 32475176
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional changes in an Australian high-level drug trafficking network after exposure to supply changes.
O'Reilly MJA; Hughes CE; Bright DA; Ritter A
Int J Drug Policy; 2020 Oct; 84():102797. PubMed ID: 32763755
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of performance-enhancing drugs seized by Israeli enforcement agencies 2012-2017: implications for policy and regulatory change.
Bonny-Noach H; Berkovitz R; Shapira B
Isr J Health Policy Res; 2020 May; 9(1):14. PubMed ID: 32362275
[TBL] [Abstract][Full Text] [Related]
16. Gendered perspectives on women's anabolic-androgenic steroid (AAS) usage practices.
Piatkowski T; Robertson J; Lamon S; Dunn M
Harm Reduct J; 2023 Apr; 20(1):56. PubMed ID: 37098574
[TBL] [Abstract][Full Text] [Related]
17. Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma.
van Beek I; Chronister KJ
Int J Drug Policy; 2015 Sep; 26(9):868-74. PubMed ID: 26118797
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Anabolic androgenic steroids used as performance and image enhancing drugs in professional and amateur athletes: Toxicological and psychopathological findings.
Piacentino D; Sani G; Kotzalidis GD; Cappelletti S; Longo L; Rizzato S; Fabi F; Frati P; Fineschi V; Leggio L
Hum Psychopharmacol; 2022 Jan; 37(1):e2815. PubMed ID: 34528289
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
